NEWARK, Calif., June 16, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (SEC). Revance expects to grant the underwriters a 30-day option to acquire an additional 450,000 shares. All of the shares in the offering are to be sold by Revance. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cowen and Company, LLC and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering, with BMO Capital Markets Corp. and William Blair & Company, L.L.C. acting as co-managers.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed public offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: email@example.com.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Revance's expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Revance will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Revance will be able to complete the proposed public offering on the anticipated terms, or at all. Revance will need to raise additional capital to fund its operations and may be unable to raise capital when needed, which would force Revance to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, Revance and its business can be found under the heading "Risk Factors" in the prospectus included in Revance's Registration Statement on Form S-1 (File No. 333-196582), initially filed with the SEC on June 6, 2014. Revance expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
CONTACT: Westwicke Partners, Investor Relations Lynn Pieper 415-202-5678 firstname.lastname@example.orgSource:Revance Therapeutics, Inc.